SG10201804750XA - Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 - Google Patents

Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Info

Publication number
SG10201804750XA
SG10201804750XA SG10201804750XA SG10201804750XA SG10201804750XA SG 10201804750X A SG10201804750X A SG 10201804750XA SG 10201804750X A SG10201804750X A SG 10201804750XA SG 10201804750X A SG10201804750X A SG 10201804750XA SG 10201804750X A SG10201804750X A SG 10201804750XA
Authority
SG
Singapore
Prior art keywords
reduction
inflammatory disease
disease symptoms
short peptides
inhibit signaling
Prior art date
Application number
SG10201804750XA
Inventor
Raymond Kaempfer
Anat Shirvan
Gila Arad
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Atox Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd, Atox Bio Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of SG10201804750XA publication Critical patent/SG10201804750XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SG10201804750XA 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28 SG10201804750XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912631P 2013-12-06 2013-12-06
US201461924869P 2014-01-08 2014-01-08

Publications (1)

Publication Number Publication Date
SG10201804750XA true SG10201804750XA (en) 2018-07-30

Family

ID=52396781

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804750XA SG10201804750XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
SG11201604512XA SG11201604512XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201604512XA SG11201604512XA (en) 2013-12-06 2014-12-07 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Country Status (7)

Country Link
US (2) US9963497B2 (en)
EP (1) EP3077415B1 (en)
JP (1) JP6757667B2 (en)
AU (2) AU2014358677A1 (en)
CA (1) CA2932150A1 (en)
SG (2) SG10201804750XA (en)
WO (1) WO2015083173A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015083173A1 (en) * 2013-12-06 2015-06-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3691672A1 (en) * 2017-10-06 2020-08-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Peptides for use in the treatment of viral infections
CN111253469B (en) * 2020-03-06 2021-09-07 暨南大学 Self-assembled short peptide and application thereof in treating acne
WO2023080790A1 (en) * 2021-11-02 2023-05-11 Tosoj As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
AU2003272065A1 (en) * 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
ES2680570T3 (en) * 2010-02-18 2018-09-10 Ose Immunotherapeutics Humanized anti-CD28 antibodies
DE102012008730A1 (en) * 2011-12-02 2013-06-06 Dr. Budz GmbH Oral composition, useful e.g. as dietary supplement, comprises monounsaturated fatty acids comprising oleic acid e.g. oleic acid-((Z)-9-octadecenoic acid) in combination with peptides consisting of specific amino acids and/or antioxidant
KR102277116B1 (en) 2012-01-16 2021-07-15 아톡스 바이오 엘티디. Synthetic Peptides for Treatment of Bacterial Infections
WO2015083173A1 (en) * 2013-12-06 2015-06-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28

Also Published As

Publication number Publication date
AU2017261479A1 (en) 2017-11-30
JP2017501999A (en) 2017-01-19
US20180215804A1 (en) 2018-08-02
CA2932150A1 (en) 2015-06-11
JP6757667B2 (en) 2020-09-23
WO2015083173A1 (en) 2015-06-11
AU2014358677A1 (en) 2016-06-02
US20160289295A1 (en) 2016-10-06
SG11201604512XA (en) 2016-07-28
US9963497B2 (en) 2018-05-08
US10280209B2 (en) 2019-05-07
EP3077415A1 (en) 2016-10-12
EP3077415B1 (en) 2020-02-12
AU2017261479B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
IL243445B (en) Silencer
HK1223340A1 (en) Dump system
GB2515794B (en) Improvements Relating to Vehicles
EP2816578A4 (en) Engineering vehicle
GB201309667D0 (en) Improvements to social alarms
SG11201604512XA (en) Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
FR3001437B1 (en) PROGRESSIVE RIGID VESSEL REDUCTION / INCREASE SYSTEM
GB201318039D0 (en) Engine system
EP2929915A4 (en) Body builder
HK1216994A1 (en) Reducing the risk of autoimmune disease
GB201316866D0 (en) Two-stage turbocharger system
GB2522110B (en) System integration
GB201319445D0 (en) Self-assembly of nanotubes
ZA201600071B (en) Pyridine-2-carboxamides as nematocides
GB201308020D0 (en) Vehicle composite structure
EP2985361A4 (en) Age-hardening steel
PT2956136T (en) D-fagomine for preventing the onset of autoimmune diseases
EP2970869A4 (en) Low-phosphate repressible promoter
EP2974517A4 (en) Motion initiated teleconference
GB201304194D0 (en) Use of cladribine for treating autoimmune inflammatory disease
IL241331A0 (en) Inhibition of neurodegenerative disease
IL239572A0 (en) Progressive lenssess
AU2013236V (en) CR001 Correa alba
GB201300231D0 (en) Car Viz
GB201407493D0 (en) Emergency system